Company profile: Pharming
1.1 - Company Overview
Company description
- Provider of protein replacement therapies and precision medicines, including Joenja (leniolisib), an oral, selective PI3Kδ inhibitor approved to treat activated phosphoinositide 3-kinase delta syndrome (APDS) in patients aged 12 and older.
Products and services
- Joenja (leniolisib): Oral, selective PI3Kδ inhibitor approved for treating activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in patients aged 12 and older
- Regulatory-approved
- Precision Medicines: Pharming Group develops precision medicines within its biopharma portfolio for patient therapies
- Custom-engineered
- Protein Replacement Therapies: Pharming Group develops protein replacement therapies for therapeutic use in patients
- Clinical-grade
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Pharming
Aspreva Pharmaceuticals
HQ: Canada
Website
- Description: Provider of pharmaceutical solutions focused on identifying, developing and commercializing new indications for approved drugs and drug candidates for underserved patient populations. Headquartered in Victoria, British Columbia, the company uses a collaboration strategy termed 'indication partnering'.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aspreva Pharmaceuticals company profile →
Amryt Pharma
HQ: Ireland
Website
- Description: Provider of specialty pharmaceuticals for rare and orphan diseases: Myalept/Myalepta (metreleptin) for leptin deficiency complications in generalized or partial lipodystrophy; Mycapssa (octreotide capsules) for long-term maintenance therapy in acromegaly; Juxtapid/Lojuxta (lomitapide) for adults with HoFH; Filsuvez (Oleogel-S10) for partial-thickness wounds in junctional and dystrophic EB; and AP103, a pre-clinical gene therapy for DEB.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amryt Pharma company profile →
Phathom Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical development focused on vonoprazan, a potassium-competitive acid blocker under clinical study for acid-related gastrointestinal disorders, including GERD and H. pylori. Activities include the pHalcon-NERD Phase 2 on-demand and Phase 3 daily dosing trials for NERD, and an Expanded Access Policy (no products currently available through this program).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Phathom Pharmaceuticals company profile →
Aeovian Pharmaceuticals
HQ: United States
Website
- Description: Provider of therapeutics for rare and age-related diseases, focused on discovering, developing, and commercializing treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aeovian Pharmaceuticals company profile →
Casma Therapeutics
HQ: United States
Website
- Description: Provider of autophagy-based drug discovery and the PHLYT platform that initiates target-specific autophagic degradation of disease targets, including those beyond the ubiquitin-proteasome system, to design new medicines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Casma Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Pharming
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Pharming
2.2 - Growth funds investing in similar companies to Pharming
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Pharming
4.2 - Public trading comparable groups for Pharming
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →